52results about How to "Wide recognition" patented technology

A virtual simulator method and system via a communication network with possible physics law respect is used to create a virtual skill training environment for dexterity fulfillment of physical activities such as professional work, labour or craft activities, sport or even physical rehabilitation requirements where the skills or neuromuscular ability is required to be performed in a precise environment. All information required insuring a code of conduct, state-of-the-art, physic laws, technical code and technique for physical activities training certification for a member are managed and maintained in a database by an online processor. This database is maintained for continuous neuromuscular training improvement updates. Access to a third party witness in this training program is allowed to ensure code, law and state-of-the-art integrity when certification is required.

An analysis method for five-differential complete blood cell based on visual image is provided. The analysis method for five-differential complete blood cell is carried out in two channels. The method includes: counting blood cells by typical cytometry to obtain the amount of blood cells; identifying and counting the blood cells by image recognition to obtain the percent of each kind of blood cells; then calculating the results from the two channels to obtain the number of each kind of blood cells.

The invention provides a PSCA (prostate stem cell antigen) and PD-L1 targeted CAR based on OCTS (one CAR with two ScFvs)-CAR (chimeric antigen receptor), an encoding gene, an OCTS-CAR-T recombinant expression vector as well as a construction method and an application of the OCTS-CAR-T recombinant expression vector. The PSCA and PD-L1 targeted CAR comprises a CD8 leader membrane receptor signal peptide, a double-antigen binding region, a CD8 Hinge chimeric receptor linker, a CD8 Transmembrane chimeric receptor transmembrane region, a CD28 chimeric receptor co-stimulator, an OX40 chimeric receptor co-stimulator and a TCR chimeric receptor T-cell activation domain which are connected in series sequentially, wherein the double-antigen binding region comprises heavy chains VH and light chains VL of PSCA and PDL1 single-chain antibodies, Inner-Linker in antibodies and Inter-Linker among the single-chain antibodies, which are in series connection or turn connection. Besides, the invention provides the encoding gene of the PSCA and PD-L1 targeted CAR, the recombinant expression vector as well as the construction method and the application of the recombinant expression vector.

The invention provides an OCTS-CAR technique-based OCTS-CAR double-targeting chimeric antigen receptor, a coding gene and a recombinant expression vector and establishment and application of the OCTS-CAR double-targeting chimeric antigen receptor, the coding gene and the recombinant expression vector. The OCTS-CAR double-targeting chimeric antigen receptor includes a CD8 leader membrane receptor signal peptide, a double-antigen binding region, a CD8 Hinge chimeric receptor gemel, a CD8 transmembrane chimeric receptor transmembrane region, a CD28 chimeric receptor co-stimulatory factor, a CD134 chimeric receptor co-stimulatory factor and a TCR chimeric receptor T cell activating domain which are connected sequentially and in series, wherein the double-antigen binding region comprises heavy-chain VH and light-chain VL, connected in a certain mode, of two single-chain antibodies, an antibody Inner-Linker and an Inter-Linker between single-chain antibodies, and the two single-chain antibodies are formed by combining any two of a BCMA single-chain antibody, a CD319 single-chain antibody, a CD38 single-chain antibody, a PDL1 single-chain antibody and a CD123 single-chain antibody; in addition, the invention further provides a gene encoding the OCTS-CAR double-targeting chimeric antigen receptor, the recombinant expression vector and an establishment method and application of the gene encoding the OCTS-CAR double-targeting chimeric antigen receptor and the recombinant expression vector.

The invention discloses a method for recognizing lithology through reconstructed textures. The method comprises the following steps: establishing an original specimen image library; establishing a standardized image library; extracting features of the rock specimen image by using discrete convolution and maximum pooling operation of a convolutional neural network MobileNet-V2 convolutional model,and effectively preventing the problems of gradient explosion and gradient disappearance in the image feature extraction process by using a new algorithm; and selecting the rock category with the maximum probability to output a result, and completing the recognition process. According to the method, the problems of low precision and low recognition efficiency caused by the fact that an existing algorithm is limited to two dimensions in the field of randomly recognizing rock lithology under the conditions of particle distribution and section texture development and imaging quality including rock color, definition and the like are solved. The method has the advantages that various lithology characters can be widely identified without being limited by external factors such as backgrounds andcolors, and the identification accuracy is improved; intelligent identification operation speed improvement.

The invention discloses an OCTS (One CAR (Chimeric Antigen Receptor) with two ScFvs (Single-chain variable Fragments)) technique based CAR-T (Chimeric Antigen Receptor-T cell immunotherapy) therapeutic vector for glioblastoma. The OCTS technique based CAR-T therapeutic vector comprises a lentiviral skeleton plasmid, a human EF1 [alpha] promoter (SEQ ID NO. 14), an OCTS chimeric receptor structural domain and a PDL1 single-chain antibody, wherein the OCTS chimeric receptor structural domain comprises a CD8 leader chimeric receptor signal peptide (SEQ ID NO. 15), a PDL1 single-chain antibody light chain VL (SEQ ID NO. 16), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO. 17), an EGFRvIII single-chain antibody light chain VL (SEQ ID NO. 18), an EGFRvIII single-chain antibody heavy chain VH (SEQ ID NO. 19), an antibody Inner-Linker (SEQ ID NO. 20), a single-chain antibody Inter-Linker (SEQ ID NO. 21), a CD8 Hinge chimeric receptor linker (SEQ ID NO. 22), a CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO. 23), a TCR (T Cell Receptor) chimeric receptor T cell activation domain (SEQ ID NO. 26) and a chimeric receptor co-stimulator domain. In addition, the invention also discloses a construction method of the vector and application of the vector to the preparation of a medicine for treating the glioblastoma.

The invention discloses a marker used for in-vivo tracing and manual removal of CAR-T cells. The marker comprises a trace-linker 1 with a sequence as shown in SEQ ID No. 18, a trace-linker 2 with a sequence as shown in SEQ ID No. 19 and a trace-linker 3 with a sequence as shown in SEQ ID No. 19. The invention also discloses a CAR-T therapy vector including the marker and a construction method thereof. Moreover, the invention further discloses application of the marker to preparation of the CAR-T therapy vector and drugs used for treating triple-negative breast cancer. The marker provided by the invention can realize controllable in-vivo tracing, in-vitro separation and manual removal of CAR-T cells without influence on the tumor killing effect of the CAR-T cells, so the security of CAR-T cell therapy is greatly improved, and a powerful pool can be provided for deeper analysis of the process of CAR-T cell therapy. The vector provided by the invention can express a targeting chimeric antigen receptor of CD117 in human T lymphocytes, guides and activates killing effect of T lymphocytes on CD117 positive cells, and is applicable to treatment of triple-negative breast cancer in clinical practice.

The invention discloses a high-accuracy optical imaging device based on quantum statistics. The high-accuracy optical imaging device comprises a laser confocal microscopic device (1), a single-photon counting statistical unit (2) and a master control device (3), wherein the laser confocal microscopic device (1) is used for stimulating a sample, collecting fluorescence emitted by the sample and guiding the fluorescence into the single-photon counting statistical unit (2); the single-photon counting statistical unit (2) is used for receiving a fluorescence signal from the laser confocal microscopic device (1), generating a plurality of single-photon counting signals and multiphoton coincidence counting signals and outputting the plurality of single-photon counting signals and the multiphoton coincidence counting signals to the master control device (3); and the master control device (3) is respectively connected with the laser confocal microscopic device (1) and the single-photon counting statistical unit (2) and used for generating control signals and respectively outputting the control signals to the laser confocal microscopic device (1) and the single-photon counting statistical unit (2) so as to control confocal scanning of the laser confocal microscopic device (1) to be synchronous with data collection of the single-photon counting statistical unit (2). The high-accuracy optical imaging device based on quantum statistics can provide high-accuracy imaging and resolution of adjacent objects, and the accuracy of the high-accuracy optical imaging device based on quantum statistics is not limited by the Rayleigh limit.

The invention provides a high robustness audio fingerprint identification method and system. The method comprises the following steps audio frequency data to be identified is obtained and subjected topreprocessing operation, preprocessed audio data to be identified is orderly subjected to frequency domain transformation and Bark domain transformation, all sub-band energy is used as primitive characters of the audio data to be identified, the primitive characters are subjected to correcting operation, corrected primitive characters are used as robustness characteristics of the audio data to beidentified, audio fingerprint modeling operation is performed according to the robustness characteristics of the audio data to be identified, audio fingerprints to be identified corresponding to theaudio data to be identified are generated, a preset audio fingerprint database is loaded, the audio fingerprints to be identified are matched with standard audio fingerprints in the audio fingerprintdatabase, and the audio fingerprints to be identified are identified. According to the method, the robustness characteristics are used to generate the audio fingerprints to be identified which are then matched with the standard audio fingerprints, robustness of identification processes can be improved, and accuracy of identification results can be improved.

The invention discloses a CAR-T vector capable of targeting Her2 and blocking PD-L1 to reduce tumor immune escape. The CAR-T vector comprises a human EF1 alpha promoter for eukaryotic transcription ofa chimeric antigen receptor gene, wherein the human EF1 alpha promoter is shown in the formula of SEQ ID NO. 1, a second-generation CAR or third-generation CAR chimeric antigen receptor combining recognition, delivery and starting, wherein the chimeric antigen receptor comprises a Her2 single-chain antibody light chain VL and a Her2 single-chain antibody heavy chain VH, an IRES ribosome binding sequence shown in the formula of SEQ ID NO. 10, PD-L1 scFv and a gene transfer vector. The invention discloses a construction method of the vector and a use of the vector in preparation of drugs for reducing tumor immune escape. Through a Her2 CAR-T technology and PD-L1 scFv expressed in the T lymphocytes, the PD-L1 on the surface of the tumor cells is blocked, the interaction between PD-1 and PD-L1 is inhibited, tumor cell immune escape is inhibited and the T lymphocyte effects of killing tumor cells are improved so that the CAR-T immunotherapy effects of resisting brain glioma are improved.

The present invention relates to a binding polypeptide specifically binding to the amino acid sequence W-V-N-X¹-F-Y-X² (SEQ ID NO: 1), wherein X¹ represents any amino acid, preferably Q or P, and wherein X² represents any amino acid, preferably, T or S in a norovirus polypeptide. The present invention further relates to polynucleotide encoding a binding polypeptide of the present invention an to a host cell comprising the same or the polynucleotide of the invention. The present invention further relates to a method of detecting the presence of a norovirus capsid polypeptide in a sample and to kits, devices, and uses making use of the binding peptide of the invention.

The invention discloses a CAR-T vector capable of targeting Her2 and disturbing PD-L1 to reduce tumor immune escape. The CAR-T vector comprises a human EF1 alpha promoter for eukaryotic transcriptionof a chimeric antigen receptor gene, wherein the human EF1 alpha promoter is shown in the formula of SEQ ID NO. 1, PD-1 shRNA in the 3'UTR, wherein the sequence of the PD-1 shRNA is shown in the formula of SEQ ID NO. 25, a gene delivery vector, and a second-generation CAR or third-generation CAR chimeric antigen receptor combining recognition, delivery and starting, wherein the chimeric antigen receptor comprises a Her2 single-chain antibody light chain VL and a Her2 single-chain antibody heavy chain VH. The invention also discloses a construction method of the vector and a use of the vector in preparation of drugs for disturbing PD-L1 to reduce tumor immune escape. Through a Her2 CAR-T technology and interference of PD-1 expression in T lymphocytes, the tumor immune escape is inhibited and the T lymphocyte effects of killing tumor cells are improved so that the CAR-T immunotherapy effects of resisting brain glioma are improved.

A touchpad includes at least one supporting plate and at least one flexible printed circuit fixed to the supporting plate. The supporting plate includes at least one first electrical protection track, made by a conductive ink, connected to at least one connection track with a predetermined value of potential and at least one connection track for connection towards a processor.

The invention discloses a CRISPR/RfxCas13d anti-plant RNA virus vector and a construction method and application thereof. The vector comprises a pCambia 1300-RfxCas13d recombinant vector, the recombinant vector is composed of a CaMV 35S promoter, a hygromycin gene, a CaMV poly(A) signal terminator, a pVS1 RepA, a pVS1 replication starting point, a CaMV 35S promoter, an RfxCas13d gene and an NOS terminator, the sequence of the RfxCas13d gene is as shown in SEQ ID No. 1, and the sequence of the NOS terminator is as shown in SEQ ID No. 2. Turnip mosaic virus (TuMV-GFP) infectious clone with a GFPfluorescent label is used for indicating RNA viruses to naturally invade plants, and RNA can be directionally cut at a specific position through combination of RfxCas13d protein and sgRNA. The vectorconstructed by the invention can effectively inhibit infection of TuMV, provides a new strategy for prevention and control of plant virus diseases, and has important production significance.

The present invention has revealed the compounds transportable by ATB<0+>. Based on the information about these compounds, drugs transportable by ATB<0,+> may be designed, produced and screened. Such drugs may serve to treat and/or prevent the diseases in which NOS, phenylglycine, carnitine, D-amino NOS, phenylglycine, carnivolved. The ATB<0,+> gene may be administered to patients to be used for gene therapy of the diseases as described above.

A system for contextualising an unstructured stream of text, representative of spoken word, including a grammar processor, a sentence processor, a frequency processor, a summer and an emotion processor. The unstructured stream of text is processed and outputs an audio file total for each matched phrase, word and proper noun, determined from the unstructured text, to a data significance processor. The data significance processor receives and audio file total for each name, proper noun and matched real phrase, determined from the unstructured text, and outputs a list including the names, proper nouns and matched real phrases in order of contextual significance.

The invention provides a face recognition method. The method comprises the following steps that: a deep network model is built, training data are obtained, and the deep network model is trained; the original image of a human face is obtained, and a depth-of-field image corresponding to the original image is obtained at the same time; whether the original image is a real person image or not is judged through a preset face detection method according to the original image and the depth-of-field image; and if yes, the original image is matched with the matching image of a to-be-matched person pre-stored in an image database through the deep network model, and a matching result is outputted. According to the face recognition method provided by the invention, a deep learning mode of transfer learning is adopted to train the deep network model; the face detection method is adopted to detect whether an original image is a real person image or a picture. The invention further correspondingly provides a face recognition device and a computer storage medium. By utilizing the face recognition method, the real person image can be accurately distinguished, the unknown person can be accurately recognized, recognition accuracy is high, and an application range is wide.

The invention discloses an OCTS technology-based prostatic cancer CAR-T therapy vector which comprises a lentivirus framework plasmid, a human EP1alpha promoter (SEQ ID NO.14), an OCTS chimeric receptor structure domain and a PDL1 single-chain antibody, wherein the OCTS chimeric receptor structure domain comprises A CD8 leader chimeric receptor signal peptide (SEQ ID NO.15), a PSMA single-chain antibody light chain VL (SEQ ID NO.16), a PSMA single-chain antibody heavy chain VH (SEQ ID NO.17), a PDL1 single-chain antibody light chain VL (SEQ ID NO.18), a PDL1 single-chain antibody heavy chain VH (SEQ ID NO.19), an antibody Inner-Linker (SEQ ID NO.20), a single-chain antibody Inter-Linker (SEQ ID NO.21), a CD8 Hinge chimeric receptor hinge (SED ID NO.22), a CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO.23), a TCR chimeric receptor T cell activation domain (SEQ ID NO.26) and a chimeric receptor co-stimulus factor domain. In addition, the invention further discloses a construction method of the vector and an application of the vector in preparation of drugs for treating a prostatic cancer.

The invention relates to the technical field of semantic analysis, in particular to an NLP-based mobile phone short message recognition method and related equipment, and the method comprises the steps: obtaining the short message content of any one short message in a mobile phone short message, carrying out the word segmentation through employing a natural language processing technology, carryingout the correlation judgment, and determining a keyword corresponding to the short message content through a judgment result; judging whether any short message is a junk short message or not accordingto the keyword, marking the identified mobile phone short message, and shielding or deleting the mobile phone short message when the mobile phone short message is identified as the junk short message; and calling an automatic voice playing function to carry out voice playing on the mobile phone short message which is identified as the non-junk short message. According to the method, the keywordsare extracted from the short message content, the keywords are subjected to relevancy judgment, and then whether the short message content belongs to the spam short message range or not is identified,so that the effects that the identification degree of the spam short message is wide, the identification method is not easy to bypass, and the effective short message content is automatically playedare achieved.

The invention discloses a CAR-T carrier targeted at EGFRvIII to interfere PD-1 and reduce tumor immune escape, the CAR-T carrier comprises a human DF1 alpha promoter, PD-1shRNA in 3'UTR, a gene transfer carrier and a second generation CAR or third generation CAR, wherein the human DF1 alpha promoter is used for transcribing CAR genes and shown as SEQ ID NO. 1; and the sequence of the PD-1shRNA isshown as SEQ ID NO. 25; the second generation CAR or third generation CAR is used for integrating recognition, transmitting and starting and comprises an EGFRvIII single-chain antibody light chain VLand an EGFRvIII single-chain antibody heavy chain VH. Besides, the invention discloses a construction method of the carrier and application of the carrier in preparation of drugs for interfering the PD-1 to reduce tumor immune escape. According to the CAR-T carrier targeted at the EGFRvIII to interfere the PD-1 and reduce tumor immune escape and the construction method and the application, the CAR-T technology aiming at the SGFRvIII is used, tumour cell immune escape is inhibited by interfering the expression of the PD-1 in the T lymphocyte, killing to the tumour cells by the T lymphocyte is enhanced, and accordingly, the glioma resistance effect of the CAR-T immunotherapy is improved.